REMARKS

Reconsideration of this application is requested in view of the amendments to the specification and claims and the remarks presented herein.

The claims in the application are claims 4 to 8 and 16 to 31, all other claims having been cancelled. Applicants have renumbered the claims in accordance with the Examiner's suggestion.

A new Abstract of the Disclosure is submitted herewith and a brief description of the drawings has been inserted into the specification. Applicants are submitting herewith copies of Figures 5 and 10 with proposed corrections in red for approval by the Examiner.

Claims 4 to 8 and 16 to 31 were rejected under 35 USC 112, second paragraph, as being indefinite. Claim 21 has been amended to insert reference to a dipeptide compound to obviate the Examiner's objection to the dependency of the other claims thereon. The "and/or" language has been replaced by Markush terminology in claim 4 and the 1,10.-diol has been corrected. Claims 16 and 20 are now dependent upon claim 21 and the

typographical errors noted in the claims have been corrected. It is believed that the

amended claims now comply with 35 USC 112 and withdrawal of this ground of

rejection is requested.

Claims 4, 6, 21, 22 and 24 to 31 have been amended to overcome the Examiner's

objection thereto and the Examiner's kind assistance in this matter is appreciated.

In view of the amendments to the specification and claims and the above remarks,

it is believed that the claims clearly point out Applicants' patentable contribution and

favorable reconsideration of the application is requested.

Respectfully submitted, Muserlian, Lucas and Mercanti

Charles A. Muserlian, 19,683

Attorney for Applicants

Tel. # (212) 661-8000

CAM:ds Enclosures

14